Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
News > Health News
Audio By Carbonatix
9:00 AM on Thursday, October 30
The Associated Press
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 30, 2025--
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.
To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations. The webcast will be archived and available for replay for 90 days following the event.
About Amylyx Pharmaceuticals
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251030438814/en/
CONTACT: Media
Amylyx Media Team
+1 (857) 320-6191
Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH OTHER SCIENCE GENERAL HEALTH RESEARCH PHARMACEUTICAL SCIENCE
SOURCE: Amylyx Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 10/30/2025 09:00 AM/DISC: 10/30/2025 09:00 AM
http://www.businesswire.com/news/home/20251030438814/en